Funding Opportunity PAR-19-051 from the NIH Guide for Grants and Contracts. This is a reissue of the Emerging Global Leader Program (K43) to align with the clinical trials policy.

With training in precision medicine, human genetics, predictive modeling, artificial intelligence, biomedical informatics, bioinformatics, or related field....
From Marshfield Clinic Health System - Fri, 02 Nov 2018 13:16:14 GMT - View all Marshfield, WI jobs

Funding Opportunity RFA-AG-20-004 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications for P30 Alzheimer's Disease Research Centers. NIA-designated Alzheimer's Disease Research Centers (ADRCs) serve as major sources of discovery into the nature of Alzheimers disease (AD) and related dementias and into the development of more effective approaches to prevention, diagnosis, care, and therapy. They contribute significantly to the development of shared resources that support dementia-relevant research, and they collaborate and coordinate their research efforts with other NIH-funded programs and investigators.

Funding Opportunity PA-19-049 from the NIH Guide for Grants and Contracts. The development of more effective means for diagnosing and treating heart, lung, blood, and sleep (HLBS) disorders is often aided bya detailed understanding of normal biology, specifically the nature and operations of the molecular systems and cells that are affected by those diseases. ?Areas of?r?e?s?e?a?r?c?h? ?i?n?t?e?r?e?s?t?include? ?s?t?u?d?i?e?s? ?o?f? ?f?u?n?d?a?m?e?n?t?a?l? ?p?r?o?c?e?s?s?e?s? ?t?h?a?t?explain resilience the capability of some individuals to maintain or restore normal function despite aging or exposurethat causes disease in others.This Program Announcement FOA will support pilot studies by R01-funded investigators in areas of research that advance high priority studies of normal biology and resilience as described by Objective 1 of the NHLBI Strategic Vision.

Notice NOT-OD-19-023 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-19-048 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications to use NIH-funded omics capacity to carry out studies of the genetic basis and/or omics signatures of common, complex heart, lung, and blood disorders. Successful applicants will provide biospecimens for whole genome sequencing or other omics assays. No funding will be provided under this FOA. The omics data and related phenotypic data will be deposited in a public database such as dbGaP.

The Stewart Bioinformatics Group is a computational biology group focusing on developing methods for analysis of large biomedical datasets....
From Morgridge Institute for Research - Thu, 01 Nov 2018 15:51:42 GMT - View all Madison, WI jobs

This position is available in the Thomson Lab in Regenerative Biology, helping to develop a bioinformatics pipeline automating the analysis of RNA-Seq data.... $12 - $15 an hour
From Morgridge Institute for Research - Thu, 01 Nov 2018 15:51:41 GMT - View all Madison, WI jobs

Funding Opportunity RFA-CA-19-018 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. This purpose of this FOA is to promote research in colorectal cancer (CRC) screening, follow-up, and referral-to-care among target populations for whom screening rates are below national standards. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (BRP): Prevention and Screening: Implementation of Evidence-based approaches. The Accelerating Colorectal Cancer Screening and Follow-up through Implementation Science (ACCSIS) program will provide an evidence base for multilevel interventions that increase rates of CRC screening, follow-up, and referral-to-care, and best practices for how multilevel interventions can be scaled-up to reduce the burden of colorectal cancer on the United States (U.S.) population. The UG3/UH3 projects in response to this FOA must apply for both the UG3 and UH3 phases together in the single application. The UG3 effort is to be used for the development of one-year, milestone-driven planning phase (UG3), with possible rapid transition to the second phase (UH3) for clinical trials. UH3s will be awarded after administrative review of eligible UG3s that have met the scientific milestones and feasibility requirements necessary for the UH3 phase, depending on availability of funds.

Negotiable: Paramount Recruitment: Software Developer Cancer Diagnostics, Bioinformatics, Permanent A fantastic new opportunity has become available for an experienced Software Developer to join a Biotechnology company in the Hamburg region. Hamburg, Germany

Funding Opportunity PA-19-050 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to develop and test strategies to increase the engagement of men in HIV prevention and care within global settings and among US domestic populations who have evidenced lower rates of engagement and retention in HIV prevention and care. The R21 Exploratory/Developmental Grant supports studies that may involve considerable risk but may lead to a breakthrough in a particular area; or to the development of novel techniques, agents, methodologies, models; or applications that could have a major impact on a field of biomedical, behavioral, or clinical research.

Funding Opportunity PA-19-042 from the NIH Guide for Grants and Contracts. Standard AIDS dates apply , by 5:00 PM local time of applicant organization. All types of AIDS and AIDS-related applications allowed for this funding opportunity announcement are due on these dates. The first application due date for this FOA is January 7, 2019. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Interaction across company, in particular with bioinformatics team members who use R&D genomics tools for application to diagnostic system....
From Indeed - Wed, 31 Oct 2018 18:11:38 GMT - View all Redmond, WA jobs

Interaction across company, in particular with bioinformatics team members who use R&D genomics tools for application to diagnostic system....
From Indeed - Wed, 31 Oct 2018 18:07:54 GMT - View all Kirkland, WA jobs

Funding Opportunity PA-19-043 from the NIH Guide for Grants and Contracts. Genome-wide association studies and other disease studies have identified many variants that are statistically associated with disease risk, disease protection, or other traits. However, such studies do not generally show which specific variants in genomic elements cause these effects, or how they result in differences in function. Similarly, genomic sequencing studies in clinical settings have identified many variants in healthy and diseased individuals. However, the pathogenicity of such variants is often unknown, leading to their classification as variants of uncertain significance (VUS), which makes clinical implementation difficult. This Program Announcement which has companion R21 and R01 Program Announcements aims to support the development of novel and generalizable commercialized approaches to study how genetic variants lead to differences in function and to study how such functional differences affect human health and disease processes or how this knowledge can be used clinically.

Funding Opportunity PA-19-046 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) seeks Exploratory/Developmental Research Grants (R21) applications on Augmentative and Alternative Communication (AAC) to advance our scientific knowledge in the evaluation and treatment of individuals with severe speech and physical impairments, (SSPI). AAC is a set of tools and strategies that an individual uses to solve everyday communicative challenges. Augmentative and alternative communication (AAC) helps millions worldwide who cannot rely on their natural speech to communicate. This FOA is for R21s only and encourages a range of research inclusive of basic, clinical, and translational.

Funding Opportunity PA-19-047 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) seeks Research Project Grants (R01) applications on Augmentative and Alternative Communication (AAC) to advance our scientific knowledge in the evaluation and treatment of individuals with severe speech and physical impairments, (SSPI). AAC is a set of tools and strategies that an individual uses to solve everyday communicative challenges. Augmentative and alternative communication (AAC) helps millions worldwide who cannot rely on their natural speech to communicate. This FOA is for R01s only and encourages a range of research inclusive of basic, clinical, and translational.

Negotiable: Paramount Recruitment: Senior Cancer Bioinformatician 100,000 Genomes Project - Bioinformatics - Central London! Paramount are working in partnership with Genomics England to expand their team in order to deliver success with the 100,000 Genomes Project. London, England

Funding Opportunity PAR-19-045 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to stimulate research to examine the multi-dimensional foundations, experiences and management of complex, advanced signs and symptoms at the end of life.

Funding Opportunity PAR-19-044 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to stimulate research to examine the multi-dimensional foundations, experiences and management of complex, advanced signs and symptoms at the end of life.